#Vienna #Austria #Nona Biosciences #Harbour Mice #Medical University of Vienna

Nona Biosciences Partners with Medical University of Vienna

Nona Biosciences, a prominent player in the biotechnology sector, has recently established a research partnership with the Medical University of Vienna, known for its pioneering contributions to medical education and research. This collaboration is set to leverage Nona's proprietary H2L2 Harbour Mice® transgenic mouse technology, which plays a crucial role in the hunt for fully human antibodies specifically aimed at addressing infectious diseases.

Antibodies are indispensable components of modern medical practices, serving as the foundation for various diagnostic applications and biopharmaceuticals. Nona's innovative H2L2 Harbour Mice® technology allows for the creation of fully human antibodies by using genetically modified mice that produce antibodies with human structures following immunization. This approach paves the way for generating valuable human antibody candidates that can be utilized for scientific inquiry and potential therapeutic applications.

The agreement grants the Ignaz Semmelweis Institute, led by Prof. Florian Krammer, the opportunity to harness Nona’s cutting-edge technology for the generation and advancement of human antibodies applicable to research, diagnostics, and therapeutic purposes. While the H2L2 Harbour Mice® technology, alongside associated intellectual property rights, will remain under Nona Biosciences' ownership, the collaboration signifies a major step towards achieving breakthroughs in antiviral therapy development.

Dr. Di Hong, CEO of Nona Biosciences, expressed enthusiasm over the partnership, stating, "We are thrilled to collaborate with the Medical University of Vienna. This partnership highlights the capabilities of our H2L2 Harbour Mice® platform in accelerating the discovery of fully human antibodies for clinically significant targets. By merging our technological prowess with the scientific expertise at the Ignaz Semmelweis Institute, we aim to contribute significantly to antiviral drug development and improve global preparedness against pandemics."

Prof. Florian Krammer, the lead researcher at MedUni Vienna, acknowledged the advantages offered by this partnership, saying, "Having access to Nona's advanced technology enhances our ability to generate and characterize human antibodies targeting vital biological elements, particularly viral spike proteins. This collaboration lays the groundwork for developing antiviral therapies tailored for future pandemic challenges."

Nona Biosciences operates as a fully owned subsidiary of HBM Holding Limited and is committed to fostering biotherapeutic innovation through state-of-the-art technology platforms and integrated solutions. Their offerings extend from early concept development through various stages of preclinical research, facilitating the move towards Investigational New Drug (IND) applications and early clinical trials.

The company’s unique Harbour Mice® platform produces fully human monoclonal antibodies in several formats, including the classical H2L2 structure, and the heavy chain-only (HCAb) format. The HCAb Harbour Mice® stands out as the first transgenic mouse of its kind to gain clinical validation. This technology is adaptable across numerous applications, such as bispecific and multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), and even mRNA-based therapeutics.

By integrating various proprietary technologies, including single-B cell screening, an AI-driven drug discovery platform known as Hu-mAtrIx™, and complete preclinical development services, Nona Biosciences is positioned as a leader in driving the innovation of transformative next-generation therapeutics. For further details regarding their innovative approaches, visit www.nonabio.com.

As one of the top medical educational and research institutions in Europe, the Medical University of Vienna continues to shape future medical professionals and research breakthroughs. With around 9,000 students and 6,500 staff members across 30 departments, it serves as a major center for biomedical research while housing a historical medical museum, the Josephinum.

The collaboration between Nona Biosciences and the Medical University of Vienna exemplifies the partnership necessary to tackle urgent health challenges, setting a strong foundation for the development of innovative solutions in combating infectious diseases.